1. Change in spinal bone mineral density as estimated by Hounsfield units following osteoporosis treatment with romosozumab, teriparatide, denosumab, and alendronate: an analysis of 318 patients.
- Author
-
Mikula AL, Lakomkin N, Hamouda AM, Everson MC, Pennington Z, Kumar R, Pinter ZW, Martini ML, Bydon M, Kennel KA, Baffour F, Nassr A, Freedman B, Sebastian AS, Abode-Iyamah K, Anderson PA, Fogelson JL, and Elder BD
- Subjects
- Humans, Female, Male, Aged, Retrospective Studies, Middle Aged, Lumbar Vertebrae drug effects, Lumbar Vertebrae diagnostic imaging, Treatment Outcome, Aged, 80 and over, Tomography, X-Ray Computed, Teriparatide therapeutic use, Denosumab therapeutic use, Bone Density drug effects, Alendronate therapeutic use, Bone Density Conservation Agents therapeutic use, Osteoporosis drug therapy, Antibodies, Monoclonal therapeutic use
- Abstract
Objective: The purpose of this study was to determine the effect of osteoporosis medications on opportunistic CT-based Hounsfield units (HU)., Methods: Spine and nonspine surgery patients were retrospectively identified who had been treated with romosozumab for 3 to 12 months, teriparatide for 3 to 12 months, teriparatide for > 12 months, denosumab for > 12 months, or alendronate for > 12 months. HU were measured in the L1-4 vertebral bodies. One-way ANOVA was used to compare the mean change in HU among the five treatment regimens., Results: In total, 318 patients (70% women) were included, with a mean age of 69 years and mean BMI of 27 kg/m2. There was a significant difference in mean HU improvement (p < 0.001) following treatment with romosozumab for 3 to 12 months (n = 32), teriparatide for 3 to 12 months (n = 30), teriparatide for > 12 months (n = 44), denosumab for > 12 months (n = 123), and alendronate for > 12 months (n = 100). Treatment with romosozumab for a mean of 10.5 months significantly increased the mean HU by 26%, from a baseline of 85 to 107 (p = 0.012). Patients treated with teriparatide for > 12 months (mean 23 months) experienced a mean HU improvement of 25%, from 106 to 132 (p = 0.039). Compared with the mean baseline HU, there was no significant difference after treatment with teriparatide for 3 to 12 months (110 to 119, p = 0.48), denosumab for > 12 months (105 to 107, p = 0.68), or alendronate for > 12 months (111 to 113, p = 0.80)., Conclusions: Patients treated with romosozumab for a mean of 10.5 months and teriparatide for a mean of 23 months experienced improved spinal bone mineral density as estimated by CT-based opportunistic HU. Given the shorter duration of effective treatment, romosozumab may be the preferred medication for optimization of osteoporotic patients in preparation for elective spine fusion surgery.
- Published
- 2024
- Full Text
- View/download PDF